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Hidradenitis suppurativa (HS) is a chronic in-
flammatory skin condition associated with a signif-
icant social and medical cost. Patients with HS may
require emergency department care and inpatient
care, and a study found that these patients have
greater health care utilization compared with those
with psoriasis.1 The prevalence of HS in the United
States has been reported as low as 0.05%2 and as
high as 4%.3 It most commonly occurs in women
with an average age of onset of 23 years.4 Its
destructive nature can be quite debilitating, and
treatment is seldom curative. The typical lesions
include recurrent, painful nodules and abscesses in
intertriginous areas that may form sinus tracts.5 The
most common locations for HS lesions in women
are the inframammary region and the groin,
whereas for men they are the buttocks and the
perineal area.4
HS is graded on severity based on the Hurley
stages I to III. Numerous options have been
investigated for the treatment of HS; however,
most are ineffective in achieving complete remis-
sion. Treatment options are often chosen based on
disease severity and impact of the disease on
quality of life. Current treatment options include
oral zinc supplementation; laser hair removal; car-
bon dioxide (CO2) laser ablation; oral antibiotics
such as clindamycin plus rifampicin, dapsone, and
tetracyclines; and surgical unroofing and more
extensive surgical excision. Biologics and immuno-
suppressants are considered for more recalctrant
and symptomatic patients with stage III disease.4
Recent research has also found that CO2 laser
therapy has comparable recurrence rates to those
of wide excision.6Ohio State University College of Medicinea and the
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cramento, CA 95816. E-mail: lnlarsen@ucdavis.edu.We report the case of a female patient who had a
flare of HS over the entire radiation site after
treatment for ductal carcinoma in-situ (DCIS).
Radiotherapy commonly causes acute skin
toxicity, which may include erythema, edema,
and desquamation7 but to date has not been
linked to the development of HS. In the past,
radiotherapy was actually used to treat early lesions
of HS.4CASE REPORT
A 52-year-old woman with a history of HS of the
axillae, inframammary folds, and groin presented
with exacerbation of her disease. HS was diagnosed
when she was in her 30s, and her disease had been
quiescent since a 35-poundweight loss at age 40. She
would have an occasional flare in the groin, axillae,
and under her breasts but never needed any medical
treatment. A few months before this flare, DCIS was
diagnosed, and she underwent a lumpectomy along
with 6 weeks of radiation to her right breast.
Radiation dermatitis developed involving the
right breast only. She had well-demarcated, thin,
angulated erythematous, mildly scaly plaques on the
right breast. She treated this inflammation with a
petrolatum-based ointment several times daily until
the redness resolved over several weeks. As the
redness was resolving, she noted the development ofJAAD Case Reports 2016;2:44-6.
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Fig 1. Erythematous papules and open and closed
comedones on the right breast developing after radiation
dermatitis.
Fig 2. Erythematous nodules, abscesses, and sinus tracts
on the right breast in the area treated with radiation.
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breast.
On examination, over her right breast and infra-
mammary fold, she had open and closed comedones
along with erythematous papules and nodules on
the superior, lateral, and medial breast (Fig 1). The
extent of the lesions and background of hyper-
pigmentation were strikingly contained within the
distinct margins of the radiation treatment (Fig 2).
She only had a resurgence of HS in the area affected
by radiation. She did not receive hormone therapy
after lumpectomy and radiation.
This flare of HS could be categorized as Hurley
stage II disease because of the formation of recurrent
abscesses with sinus tract formation. She began
treatment of HS with oral doxycycline, topical
clindamycin 1%, and zinc supplementation. She
also received intralesional triamcinolone injections
to the inflamed papules and nodules. The topical
treatments proved to be too irritating because of the
concomitant radiation dermatitis, and she did not
notice benefit with the oral doxycycline. The steroid
injections helped control her disease, however.
DISCUSSION
The exact cause of HS is unknown. Many studies
have elicited risk factors for HS, which include
obesity, metabolic syndrome, psoriasis, Crohn’s
disease, smoking, and systemic inflammation in
general.4,8 Factors that have been associated with
increased severity of disease include male sex,
obesity, smoking pack-years, disease duration, and
lesions in the axillary, perianal, and mammary
regions.9
HS begins with follicular plugging that leads to
ductal rupture and then secondary inflammation.
Histologically, this results in perifolliculitis, follicular
hyperkeratosis, follicular hyperplasia, and epidermal
psoriasiform hyperplasia.4,10 In addition to genetic,
endocrine, and hormonal influences, the innate im-
mune system is found to play an important role in the
development of HS. Studies show that HS skin is
associated with an influx of immune cells, includingmacrophages, dendritic cells, B cells, and CD31,
CD41, and CD81 T cells. Patients with HS are also
found to have an enhancement of pro-inflammatory
cytokines, such as tumor necrosis factor alpha,
interleukin (IL)-1b, IL-10, IL-17, IL-12, and IL-23.
This enhancement has led to new developments in
the treatment of HSwith immunomodulators, such as
infliximab, adalimumab, and ustekinumab.10
Considering thepathogenesis ofHS, it is surprising
that radiotherapy would cause an exacerbation of
HS. Studies found that radiation decreases cutaneous
immunosurveillance, which would decrease the
number of immune cells in the skin, instead of
increasing them, as seen in HS.11 Radiotherapy also
induces apoptosis in tumor cells along with causing
the abscopal effect, which reduces the number of
tumor cells outside of the area of radiation. This effect
is not well understood but may be immune mediated
by increasing the number of antigen-presenting cells
and effector T cells in the skin owing to dying cancer
cells that release antigens.12 Radiotherapy, therefore,
could cause an exacerbation of HS considering the
influx of immune cells present in the skin of patients
with activeHS lesions. There is also a difference in the
intensity of radiation used in the past to treat
HS (3e8 Gy) compared with that used to treat
DCIS (50 Gy).13 The potential therefore exists to
induce more apoptosis with more radiation
inducing a greater immune response leading to a
flare of HS.REFERENCES
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